<<

. 3
( 3 .)



obese, middle–aged and older men. A randomized controlled trial. J. Am. Med. Assoc. metabolism in nondiabetic hypertensive patients. J. Intern. Med.,1997; 242: 407–12 .
274, 1915–1921 (1995) 42. Uehara MH, Kohlmann NE, Zanella MT, et al. Metabolic and haemodynamic effects of
28. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H–H, Pedersen O. Multifactorial metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes.
intervention and cardiovascular disease in patients with type 2 diabetes. N.Engl.J.Med. Metab., 2001; 3: 319–25
348, 348–393 (2003) 43. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syn-
29. Kantola I, Rouru J, Malminiemi K. et al. Effects of Metformin on Blood Pressure. A drome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic
Study in Obese Non–Diabetic Patients With Hypertension. Clin Drug Invest , 2002, 22 blood pressure, while facilitating normal menses and pregnancy. Metabolism, 1994; 43:
(6):347–354. 647–54.
30. Matthaei S., Hamann A., Klein H.H. et al. Association of metformin effect to increase 44. Dorella M., Giusto M., Da Tos V. et al. Improvement of insulin sensitivity by met-
insulin–stimulated glucose transport with potentiation of insulin–induced translocation of formin treatment does not lower blood pressure of nonobese insulin–resistant hyperten-
glucose tranporters from intracellular pool to plasma membrane in rat adipocytes. sive patients with normal glucose tolerance. J.Clin. Endocrinol. Metab., 1996, 81 (4),
Diabetes, 1991, 40 (7), 850–857 1568–1574.
31. Wollen N., Bailey C.J. Inhibition of hepatic gluconeogenesis by metformin.Synergism 45. UK Prospective Diabetes Study (UKPDS) Group. Effects of blood–flucose control with
with insulin. Biochem.Pharmacol., 1988, 37 (22), 4353–4358. metformin on complications in overweight patients with type 2 diabetes (UKPDS34).
32. Bailey C.J., Mynett K.J. Page T. Importance of the intestine as a site of Lancet, 1998, 352 (9131), 854–865.
metformin–stimulated glucose utilization. Br.J.Pharmacol.,1994, 112, 671–675. 46. Buchanan TA, Xiang Ah, Peters RK et al. Preservation of pancreatic ?–cell function
33. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta–analysis. and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in
Diabetes Care, 1999; 22 (1): 33–37. high–risk Hispanic women. Diabetes 51, 2796–2803 (2002)
34. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss 47. Grundy MA, Sempos CT, Grundy SM. Excess body weight. An under–recognized con-
in subjects with obesity with type II non–insulin–dependent diabetes. Obesity Research, tributor to dyslipidemia in white American women. Arch. Intern.Med. 154, 401–410
1998; 6 (1):47–53. (1994)
35. Makimattila S, Nikkila K, Yki–Jarvinen H. Causes of weight gain dyring insulin thera- 48. MRC/BHF Heart Protection Study of cholesterol–lowering with simvastatin in 20536
py with and without metformin in patients with type II diabetes mellitys. Diabetologia, high–risk individuals: a randomized placebo–controlled trial. Lancet 360, 7–22 (2002)
1999; 42:406–412. 49. MRC/BHF Heart Protection Study of cholesterol–lowering with simvastatin in 5963
36. Giugliano D., De Rosa N., Di Maro G. Metformin improves glucose, lipid metabolism, people with diabetes: a randomized placebo–controlled trial. Lancet 361, 2005–2016
and reduces blood pressure in hypertensive obese women. Diabetes Care, 1993, 16 (10), (2003)
1387–1390. 50. Parhofer KG, Laubach E, Barratt PHR. Effect of atorvastatin on postprandial lipopro-
37. Eschwege E.et al. BIGPRO: reducing the risk from obesity. Congress reports from tein metabolism in hypertriglyceridemic patients. J. Lipid. Res. 44, 1192–1198 (2003)
57th Congress of ADA and 16th Congress of IDF. Risques en diabetologie, 1998, 51. Wilt TJ, Rubins HB, Collins D, O’Conor TZ, Rutan GH, Robins SJ. Correlates and con-
February, pp.25–26. sequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs
38. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for car- High–Density Lipopotein Intervention Trial Study Group. Arch. Intern. Med. 156,
diovascular disease and plasminogen activator inhibitor in NIDDM subjects. Diabetes 1181–1188 (1996)


Oaaeeoa 3. I?eioeiu ea?aiea iaoaaiee?aneiai neia?iia e aai eiiiiiaioia



Iniiaiie aeoaio ia iaiaaeeaiai?
<10% Aa Iao
oicio? oa?aie?
Noaoeiu, eAIO/A?A,
Iaoaaiee?aneee neia?ii 10–20% Aa Aicii?ia
aoaoeenaeeoeeiaay eeneioa
Noaoeiu, eAIO/A?A,
>20% Aa Aa
aoaoeenaeeoeeiaay eeneioa
Aicii?ia i?e iaee?ee
Ie?o?iinou oaeee Aa Nie?aiea ia 10%
oaeoi?ia ?enea
O iaoeaioia n aunieei ?eneii
Iiauoaiea ?enea Noaoeiu,
aicii?ia eiiaeie?iaaiiay
Aeneeieaaiey iacaaeneii Aa oea?aou,
oa?aiey noaoeiu/oea?aou
io o?iaiy EIII ieaoei
eee noaoeiu/ieaoei
eAIO e A?A oiaiuoa?o ?ene ?ac?
AA – Aa Aa
aeoey NA 2 oeia e eiia?iuo oi?ae
Ia?ooaiea oiea?aioiinoe
– Aa Aa Iaooi?iei, aeeoaciiu
e ae?eica (IOA)
Ieceea aicu aoaoeenaeeoeeiaie
Oaeoi?u naa?ouaa?uae
– Aa Aa eeneiou i?e na?aa?ii–
nenoaiu e?iae
ninoaenoii ?enea >10%
O iaoeaioia
n iiauoaiiui N?A Iaae?aaaony oaaee?aiea
Ainiaeaiea – Aa yooaeoeaiinou na?aa?ii–ninoaenoiai
aoaoeenaeeoeeiaie ?enea i?e N?A>3
eeneiou auoa; noaoeiu



458 13, 7, 2005

<<

. 3
( 3 .)